Effect of heat modalities on hamstring length: a comparison of pneumatherm, moist heat pack, and a control.

STUDY DESIGN: Prospective, researcher-blinded, repeated-measures, randomized complete block design. OBJECTIVES: To compare the effects of a single treatment of Pneumatherm, moist heat pack, and a control treatment on hamstring muscle length. BACKGROUND: Traditionally, heating modalities have been used to facilitate increases in tissue length. The Pneumatherm has been developed over the past 20 years for use in the clinical treatment of a variety of musculoskeletal pathologies. However, there is no published evidence supporting the use of Pneumatherm for improving muscle length. SUBJECTS: Participants consisted of 30 healthy, college-age males taken from a convenience sampling from the University of Indianapolis student population. METHODS AND MEASURES: Participants received a 3-treatment sequence on consecutive days. Treatments involved applying the determined modality to the posterior thigh using standard treatment protocols. A hand-held dynamometer was used to establish a consistent passive measurement force to measure hamstring muscle length. RESULTS: A mixed-model analysis of variance with pretest-posttest (3 pretest and 3 posttest measures) and treatment sequence of the modalities (6 sequences of Pneumatherm, moist heat, and control) was completed. The only significant effect was for pretest-posttest measures. Post hoc comparisons revealed that the Pneumatherm posttest value was significantly different from all other measures. There were no differences found between pretest scores and the moist heat and control posttest scores. CONCLUSIONS: Our results demonstrate that the Pneumatherm modality is an effective agent for increasing hamstring muscle length following a single 20-minute treatment. In this study, a significant gain in hamstring muscle length was not found following a 1-time treatment with moist heat. The Pneumatherm may be a good option when heat is used to assist in gaining flexibility of the hamstring musculature.

Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial.

BACKGROUND: It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment. OBJECTIVE: To determine whether a 12-month course of doxycycline improves functional status in Gulf War veterans with GWVIs. DESIGN: A randomized, double-blind, placebo-controlled clinical trial with 12 months of treatment and 6 additional months of follow-up. SETTING: 26 U.S. Department of Veterans Affairs and 2 U.S. Department of Defense medical centers. PARTICIPANTS: 491 deployed Gulf War veterans with GWVIs and detectable Mycoplasma DNA in the blood. INTERVENTION: Doxycycline, 200 mg, or matching placebo daily for 12 months. MEASUREMENTS: The primary outcome was the proportion of participants who improved more than 7 units on the Physical Component Summary score of the Veterans Short Form-36 General Health Survey 12 months after randomization. Secondary outcomes were measures of pain, fatigue, and cognitive function and change in positivity for Mycoplasma species at 6, 12, and 18 months after randomization. RESULTS: No statistically significant differences were found between the doxycycline and placebo groups for the primary outcome measure (43 of 238 participants [18.1%] vs. 42 of 243 participants [17.3%]; difference, 0.8 percentage point [95% CI, -6.5 to 8.0 percentage points]; P > 0.2) or for secondary outcome measures at 1 year. In addition, possible differences in outcomes at 3 and 6 months were not apparent at 9 or 18 months. Participants in the doxycycline group had a higher incidence of nausea and photosensitivity. LIMITATIONS: Adherence to treatment after 6 months was poor. CONCLUSION: Long-term treatment with doxycycline did not improve outcomes of GWVIs at 1 year.

The antibiotic treatment trial of Gulf War Veterans' Illnesses: issues, design, screening, and baseline characteristics.

Many veterans who were deployed to the Persian Gulf during the 1990-1991 Gulf War developed multiple unexplained symptoms such as pain, fatigue, and neurocognitive problems. This constellation of symptoms has been termed Gulf War Veterans' Illnesses (GWVI). Although there is no proven explanation for the cause of GWVI, one fairly widespread explanation is systemic Mycoplasma fermentans infection. The Antibiotic Treatment Trial of GWVI is a randomized placebo-controlled trial to determine whether a 1-year course of doxycycline treatment in deployed Gulf War veterans with GWVI and testing as Mycoplasma species positive will improve their overall functional status as measured by the Physical Component Summary of the SF-36V questionnaire. The study of a multisymptom illness such as GWVI is complicated by the nonspecific nature of the illness, the unknown etiology, and the lack of a widely accepted outcome measure. The presumption of mycoplasma infection raises concerns regarding the methodology for determination of mycoplasma infection, the choice of treatment, and the duration of treatment. However, such a presumption allows the formulation of a clear testable hypothesis that can be tested with treatments with known rates of adverse events and known activity against Mycoplasma species. This paper describes the major issues faced by the investigators during planning, the study design, the patient screening results, and the baseline characteristics of the study patients. There were 2712 patients screened for study entry at 26 Department of Veterans Affairs and two Department of Defense medical centers. Of these, 491 met all study entry criteria and were randomized to either 1 year of doxycycline (200 mg/day) or 1 year of placebo. All patients were seen monthly during treatment and at 6 months after the end of treatment. Study patients had a mean age of 41 years and were mostly male (86%), white (64%), married (68%), and employed full-time (71%).